Future options with trastuzumab for primary systemic and adjuvant therapy

被引：37

作者：

Baselga, J

Gianni, L

Geyer, C

Perez, EA

Riva, A

Jackisch, C

机构：

[1] Vall Hebron Univ Hosp, Dept Med Oncol, E-08035 Barcelona, Spain

[2] Ist Nazl Tumori, I-20133 Milan, Italy

[3] Allegheny Canc Ctr, Pittsburgh, PA USA

[4] Mayo Clin, Jacksonville, FL 32224 USA

[5] Breast Canc Int Res Grp, Paris, France

[6] Univ Hosp Marburg, Marburg, Germany

来源：

SEMINARS IN ONCOLOGY | 2004年 / 31卷 / 05期

关键词：

D O I：

10.1053/j.seminoncol.2004.07.022

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：51 / 57

页数：7

共 39 条

[1]

[Anonymous], P AM SOC CLIN ONCOL

[2]

Baum M, 2003, Cancer, V98, P1802

[3] The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27 [J].

Bear, HD ;

Anderson, S ;

Brown, A ;

Smith, R ;

Mamounas, EP ;

Fisher, B ;

Margolese, R ;

Theoret, H ;

Soran, A ;

Wickerham, DL ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4165-4174

[4]

Bines J, 2003, BREAST CANCER RES TR, V82, pS56

[5]

Bouzid K., 2001, European Journal of Cancer, V37, pS167, DOI 10.1016/S0959-8049(01)81100-X

[6] Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study [J].

Burstein, HJ ;

Harris, LN ;

Gelman, R ;

Lester, SC ;

Nunes, RA ;

Kaelin, CM ;

Parker, LM ;

Ellisen, LW ;

Kuter, I ;

Gadd, MA ;

Christian, RL ;

Kennedy, PR ;

Borges, VF ;

Bunnell, CA ;

Younger, J ;

Smith, BL ;

Winer, EP .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :46-53

[7] Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer [J].

Buzdar, AU ;

Singletary, SE ;

Theriault, RL ;

Booser, DJ ;

Valero, V ;

Ibrahim, N ;

Smith, TL ;

Asmar, L ;

Frye, D ;

Manuel, N ;

Kau, SW ;

McNeese, M ;

Strom, E ;

Hunt, K ;

Ames, F ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3412-3417

[8]

BUZDAR AU, 2004, P AN M AM SOC CLIN, V23, P7

[9] Retrospective analysis of the safety of Herceptin® immunotherapy in metastatic breast cancer [J].

Cook-Bruns, N .

ONCOLOGY, 2001, 61 :58-66

[10]

EVANS T, 2002, P AN M AM SOC CLIN, V21, pA35

← 1 2 3 4 →